drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR-T)
drug_description
Allogeneic, off-the-shelf CD19-targeted CAR-T cell therapy (also referred to as REVO-UWD-19 or UWD-CD19) designed to bind CD19 on B cells and mediate T-cell activation and cytotoxic killing; administered as a single infusion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic T cells engineered with a CD19-directed chimeric antigen receptor bind CD19 on malignant B cells, triggering T‑cell activation, cytokine release, and cytotoxic killing that clears CD19+ cells (with expected on‑target B‑cell aplasia).
drug_name
UWD-19
nct_id_drug_ref
NCT06662227